Newsroom

Biotechnology

Explore the latest breakthroughs and trends in the Biotechnology sector with our newsroom. From cutting-edge innovations in gene therapy and biopharmaceuticals to advancements in medical research and regulatory updates, we provide essential insights into the scientific developments shaping the future of healthcare and life sciences.


Latest Press Releases

Dyadic Announces Second Quarter 2020 Results and Highlights Recent Company Progress
BiotechnologyEarnings

Dyadic Announces Second Quarter 2020 Results and Highlights Recent Company Progress

August 13, 2020 4:30 PM

Entered into two new collaborations with top tier animal health companies Entered into a fully funded human health collaboration with a top five global pharmaceutical company Started an animal trial for SARS-CoV-2 RBD vaccine candidate in Israel and another animal trial in European is expected to begin soon Dyadic selected by Frederick National Laboratory to engineer several C1 cell lines to express COVID-19 vaccine candidates Entered into a new...

Read more
Xenetic Biosciences, Inc. Reports Second Quarter 2020 Financial Results and Provides Corporate Update
BiotechnologyCompany Update

Xenetic Biosciences, Inc. Reports Second Quarter 2020 Financial Results and Provides Corporate Update

August 13, 2020 7:05 AM

- Successfully established two strategic academic collaborations in Q2 2020 to advance development of XCART™, its differentiated CAR T therapy platform - - Strengthened panel of experts on the Scientific Advisory Board, bringing valuable expertise across all phases of preclinical and clinical development - FRAMINGHAM, MA / ACCESSWIRE / August 13, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical...

Read more
Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration
BiotechnologyCompany Update

Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration

August 12, 2020 8:00 AM

RICHMOND HILL, ON / ACCESSWIRE / August 12, 2020 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), is a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47, today announced that it has extended its collaboration agreement with Moffitt Cancer Center ("Moffitt") for an additional...

Read more
Edesa Biotech Reports Fiscal 3rd Quarter 2020 Results
BiotechnologyEarnings

Edesa Biotech Reports Fiscal 3rd Quarter 2020 Results

August 12, 2020 7:45 AM

TORONTO, ON / ACCESSWIRE / August 12, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three and nine months ended June 30, 2020 and provided an update on its business. During the quarter, Edesa received Canadian regulatory approval to begin a Phase 2/Phase 3 clinical study of its biologic drug candidate, EB05, as a potential treatment for hospitalized COVID-19...

Read more
Nascent Biotech Reduces Liabilities by Over 1.8 Million Dollars
BiotechnologyCompany Update

Nascent Biotech Reduces Liabilities by Over 1.8 Million Dollars

August 11, 2020 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / August 11, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) Announced today that It has significantly reduced its liabilities through stock conversion and payment of accrued liabilities. The reduction was achieved through the conversion of $1,600,000 in debt to equity and the payment of over $200,000 of liabilities. Nascent's CFO Lowell Holden stated, "I believe the Company has continued to be undervalued and the debt...

Read more
Molecular Partners Announces Agreement with Swiss Government, Securing Rights to Purchase Doses of First Anti-COVID-19 DARPin(R) Program
BiotechnologyInvestor Relations

Molecular Partners Announces Agreement with Swiss Government, Securing Rights to Purchase Doses of First Anti-COVID-19 DARPin(R) Program

August 11, 2020 1:00 AM

Swiss Government will pay a reservation fee for the right to purchase up to 3.2 million doses of anti-COVID-19 DARPin® candidate, MP0420, for both therapeutic and potential prophylactic use Purchase of these doses may occur following appropriate marketing authorization Multi-specific antiviral program demonstrates best-in-class potency against live SARS-CoV-2 virus; Recent in vivo data additionally supportive of clinical...

Read more
Hancock Jaffe Regains Compliance with Nasdaq Stockholder's Equity Rule
BiotechnologyCompany Update

Hancock Jaffe Regains Compliance with Nasdaq Stockholder's Equity Rule

August 10, 2020 8:30 AM

IRVINE, CA / ACCESSWIRE / August 10, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that HJLI has received formal notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has evidenced full compliance with the stockholders' equity requirement for the continued listing of its shares on The Nasdaq Capital Market and, as a result, the...

Read more
Pieris Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
BiotechnologyEarnings

Pieris Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update

August 10, 2020 7:00 AM

Company to Host an Investor Conference Call on Monday, August 10, 2020 at 8:00 AM EDT PRS-060/AZD1402 phase 2a trial in asthma to start in fourth quarter Signed clinical trial collaboration agreement with Lilly for supply of ramucirumab for phase 2 trial of PRS-343 PRS-343 phase 2 trial in gastric cancer to start this year PRS-343 phase 1 data to be presented in oral presentation session at ESMO Achievement of preclinical milestone...

Read more
Pieris and Lilly Enter Into a Clinical Trial Collaboration to Evaluate Combination of PRS-343 With Ramucirumab and Paclitaxel in Gastric Cancer
BiotechnologyCompany Update

Pieris and Lilly Enter Into a Clinical Trial Collaboration to Evaluate Combination of PRS-343 With Ramucirumab and Paclitaxel in Gastric Cancer

August 10, 2020 6:30 AM

BOSTON, MA / ACCESSWIRE / August 10, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that it has entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company to evaluate the safety and efficacy of combining Pieris'...

Read more
Tetra Bio-Pharma Virtually Opens the Market
BiotechnologyCompany Update

Tetra Bio-Pharma Virtually Opens the Market

August 7, 2020 10:30 AM

OTTAWA, ON / ACCESSWIRE / August 7, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that TBP common shares and warrants are now listed on the TSX (the "Common Shares") and (the "Warrants"). This occurred on August 4th, 2020. Dr. Guy Chamberland, CEO and Chief Regulatory Officer, Tetra Bio-Pharma joined his team and...

Read more
Yulong Changes Name to EV Biologics
BiotechnologyCompany Name Change

Yulong Changes Name to EV Biologics

August 6, 2020 9:00 AM

CHEYENNE, WY / ACCESSWIRE / August 6, 2020 / Yulong Eco-Materials Limited (OTC PINK:YECO) today announced that it has changed its name to EV Biologics, Inc. The Company is in the process of filing the necessary forms with FINRA and CUSIP to change the name and get a new trading symbol. The Company moved its domicile from Cayman islands to Wyoming on April 12, 2019 and is currently in discussion to acquire a major USA based stem cell company...

Read more
CORRECTION FROM SOURCE: Tetra Bio-Pharma Provides Update on QIXLEEF(TM)'s European Activities
BiotechnologyCompany Update

CORRECTION FROM SOURCE: Tetra Bio-Pharma Provides Update on QIXLEEF(TM)'s European Activities

August 6, 2020 8:42 AM

Please disregard original release sent out and replace with the following. Tetra is accelerating its European activities Tetra's European project receives the approval and support from Malta Enterprise OTTAWA, ON / ACCESSWIRE / August 6, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that the Corporation is set to...

Read more
Apollo Endosurgery, Inc. Reports Second Quarter 2020 Results
BiotechnologyConference CallEarnings

Apollo Endosurgery, Inc. Reports Second Quarter 2020 Results

August 4, 2020 4:01 PM

Conference Call to Discuss Results Today at 3:30 p.m. CT / 4:30 p.m. ET AUSTIN, TX / ACCESSWIRE / August 4, 2020 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the second quarter ended June 30, 2020. Second Quarter 2020 and Recent Highlights As pre-announced, second quarter revenue was $5.6...

Read more
American CryoStem Issues Shareholder Update Letter
BiotechnologyCompany Update

American CryoStem Issues Shareholder Update Letter

August 4, 2020 8:30 AM

EATONTOWN, NJ / ACCESSWIRE / August 4, 2020 / American CryoStem Corporation (OTC PINK:CRYO) (the "Company"), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, is pleased to issue the following shareholder update letter from Chief Executive Officer John Arnone. Dear American CryoStem family, partners and...

Read more
Nascent Biotech & Manhattan BioSolutions Participate In a Panel Discussion On The TB Vaccine Development For COVID-19
BiotechnologyCompany Update

Nascent Biotech & Manhattan BioSolutions Participate In a Panel Discussion On The TB Vaccine Development For COVID-19

August 4, 2020 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / August 4, 2020 / Nascent Biotech, Inc (OTCQB:NBIO), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat cancers and viral infections, has participated in the recent expert panel discussion entitled "BCG: a therapeutic modality for COVID-19 and cancers" hosted by the Bioidea Group (https://bioidea.co/2020/07/13/bcg-covid-19/). The virtual session featured distinguished...

Read more
Insurance Carrier Denial of Coverage for Calmare Pain Mitigation Therapy(TM) Overturned in California
BiotechnologyCompany Update

Insurance Carrier Denial of Coverage for Calmare Pain Mitigation Therapy(TM) Overturned in California

August 3, 2020 12:45 PM

Independent Medical Review Organization Determined: "Denial Should Be Overturned" FAIRFIELD, CT / ACCESSWIRE / August 3, 2020 / Calmare Therapeutics Incorporated, (OTC PINK:CTTC), the pain mitigation company, announced today that the independent medical review organization ("IMRO"), in a rereview case filed with the California Department of Insurance, recommended overturning an insurance treatment coverage denial by the UnitedHealthcare...

Read more
Pieris Pharmaceuticals to Host Second Quarter 2020 Investor Call and Corporate Update on August 10, 2020
BiotechnologyCompany Update

Pieris Pharmaceuticals to Host Second Quarter 2020 Investor Call and Corporate Update on August 10, 2020

August 3, 2020 8:00 AM

BOSTON, MA / ACCESSWIRE / August 3, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a second quarter 2020 investor call on Monday, August 10, 2020 at 8:00 AM EDT to discuss financial results and provide a corporate update. To...

Read more
Helix BioPharma Corp. to Present at the SNN Network Virtual Conference
BiotechnologyConferences

Helix BioPharma Corp. to Present at the SNN Network Virtual Conference

July 31, 2020 5:05 PM

RICHMOND HILL, ON / ACCESSWIRE / July 31, 2020 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced it will be presenting at the SNN Network Virtual Conference on Monday, August 3rd at 2:30 PM EDT. Dr. Heman Chao, Helix's Chief Executive Officer will be hosting the...

Read more
ABMC Reports First Quarter 2020 Results
BiotechnologyEarnings

ABMC Reports First Quarter 2020 Results

July 31, 2020 4:00 PM

KINDERHOOK, NY / ACCESSWIRE / July 31, 2020 / American Bio Medica Corporation (OTC PINK:ABMC) today announced financial results for the three months ended March 31, 2020. Chief Executive Officer Melissa A. Waterhouse stated, "Our drug testing business has been negatively impacted by the Covid-19 pandemic. Here in the third quarter 2020, we are starting to see some improvement in drug test sales, however, as the pandemic continues, it is...

Read more
Apollo Endosurgery, Inc. to Report Second Quarter 2020 Results on August 4, 2020
BiotechnologyCompany Update

Apollo Endosurgery, Inc. to Report Second Quarter 2020 Results on August 4, 2020

July 30, 2020 4:05 PM

AUSTIN, TX / ACCESSWIRE / July 30, 2020 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results for the second quarter ended June 30, 2020 on Tuesday, August 4, 2020, after the U.S. stock markets close. Apollo will hold a conference call on Tuesday, August 4, 2020 at 3:30...

Read more

Join the thousands of ACCESS Newswire customers today who are getting millions of views on their news.


Check out our flexible subscription and pay as you go pricing

and packages.

Use Code NEWS10 for 10% off  of your first purchase.


Latest Blog Posts

Visit our blogs for press release tips, media engagement

Strategies, and Product Comparisons.

Executive delivering prepared remarks from an earnings call script
By Jennifer Hammers • July 9, 2026
How to write earnings call prepared remarks that land — structure, length, the safe-harbor open, non-GAAP language, and building remarks around your strategy.
IR
By Brian Balbirnie • July 8, 2026
A practical earnings call preparation checklist for IR teams — the two-week runway, consensus, logistics, Q&A prep, and Reg FD-clean disclosure timing.
ACCESS Newswire guide on AI investor relations — how AI assistants read company earnings disclosures
By Jennifer Hammers • July 6, 2026
AI assistants read your earnings within minutes. Learn how IR teams make disclosures AI-readable — and how the LLM Citation Score measures your visibility.
What does Meltwater cost in 2026, and what are the alternatives? Meltwater resells press release dis
By Jennifer Hammers • June 22, 2026
What does Meltwater cost in 2026, and what are the alternatives? See how ACCESS Newswire compares on distribution, data, and price.
A logo for accesswire next to a logo for rack
By Jennifer Hammers • June 21, 2026
Compare Muck Rack vs ACCESS Newswire on pricing, features, and alternatives. See how ACCESS Newswire adds distribution, pitching, and analytics.
A blue and white logo with a check mark next to it
By Jennifer Hammers • June 19, 2026
Compare Business Wire vs ACCESS Newswire on pricing and capabilities — and how ACCESS delivers comparable reach at a fraction of the cost.
Show More




Discover the news
by Industry:


Need help with your PR Strategy?
Learn more about our
professional PR Services today:

.MEDIA PRO 
Want to get noticed
by the Media but don’t
know how? 

.TOTAL PRO

Need full support to 

Optimize your PR

Efforts?